Using millers anaesthesiology book discuss in details Novel anticoagulants NOAC
Novel Anticoagulants (NOACs / DOACs)
From Miller's Anesthesia, 10th Edition
1. Introduction and Classification
| Category | Drug(s) | Target |
|---|---|---|
| Direct Thrombin Inhibitors (DTIs) | Dabigatran (Pradaxa) | Factor IIa (thrombin) |
| Direct Factor Xa Inhibitors | Rivaroxaban (Xarelto), Apixaban (Eliquis), Edoxaban (Savaysa) | Factor Xa |
— Miller's Anesthesia, 10e, Chapter 46 (Hemostasis & Anticoagulation)
2. Approved Indications
- Prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Reduction of stroke risk in nonvalvular atrial fibrillation (AF)
- In patients with AF undergoing percutaneous coronary intervention (PCI), dual therapy (a Factor Xa inhibitor + a P2Y12 inhibitor) reduces bleeding risk compared with triple therapy (VKA + ASA + P2Y12 inhibitor), though end points of death and ischemia remain unclear.
3. Efficacy vs. Warfarin
- Significant reduction in major bleeding (RR 0.86, 95% CI 0.72–1.02)
- Significantly decreased risk of intracranial hemorrhage (RR 0.46, 95% CI 0.39–0.56)
4. Individual Drugs
A. Dabigatran (Pradaxa) — Direct Thrombin Inhibitor
- First DOAC approved for stroke prevention in nonvalvular AF since warfarin
- At 150 mg twice daily: reduces stroke risk with a similar overall bleeding risk to warfarin (INR 2.0–3.0)
- Bleeding profile differs: higher risk of major gastrointestinal bleeding, but lower risk of intracranial bleeding vs. warfarin
- Monitoring challenge: aPTT is non-linear at clinically relevant concentrations (only correlates at >200 ng/mL). The thrombin time (TT) is very sensitive but cannot quantify drug levels. If monitoring is necessary, dilute TT or ecarin clotting time are the tests of choice.
B. Rivaroxaban (Xarelto) — Factor Xa Inhibitor
- Activity directed against the active site of factor Xa
- Associated with fewer strokes/embolic events, fewer intracranial hemorrhages, and lower all-cause mortality vs. warfarin
- Monitoring: anti-factor Xa assay (must be calibrated individually for each drug; therapeutic ranges not yet established)
C. Apixaban (Eliquis) — Factor Xa Inhibitor
- Compared with warfarin in patients with AF: reduction in stroke risk plus a significant reduction in major bleeding
- Monitoring: anti-factor Xa assay (same caveats as rivaroxaban)
D. Edoxaban (Savaysa) — Factor Xa Inhibitor
- Similar mechanism to rivaroxaban and apixaban
- Used for DVT/PE treatment and AF stroke prevention
- Note: the reversal agent andexanet alfa is not currently indicated for edoxaban
5. Special Populations and Dose Adjustments
- Renal or hepatic impairment — dose adjustments are drug-specific
- Extreme body weights — <60 kg or BMI >40 kg/m² may alter pharmacokinetics
- Pregnancy — LMWH is preferred over DOACs in most pregnant women requiring anticoagulation
- Mechanical heart valves — DOACs are contraindicated; use warfarin
6. Perioperative Management
6a. Preoperative Discontinuation
- The specific DOAC prescribed
- Expected procedural bleeding risk
- Renal function (eGFR)
- Whether neuraxial anesthesia is planned
| Drug | Low-bleeding risk procedure | High-bleeding risk procedure / Neuraxial |
|---|---|---|
| Dabigatran | 24 h before | 48–96 h (renal function dependent) |
| Rivaroxaban | 24 h | 48 h |
| Apixaban | 24 h | 48 h |
| Edoxaban | 24 h | 48 h |
6b. Bridging Therapy
- Some patients with mechanical heart valves (decision based on valve location and surgery type)
- Patients at high risk for recurrent thromboembolism
6c. Neuraxial Anesthesia
- Wait the recommended interval (above) after last DOAC dose before neuraxial block
- Multidisciplinary team approach (patient, primary physician, surgeon, anesthesiologist, hematologist) is essential
- Local hospital guidelines are being set in the absence of definitive RCT data
6d. Cardiac Surgery Patients on DOACs
6e. Ophthalmic Surgery
7. Reversal Agents
7a. Dabigatran Reversal — Idarucizumab (Praxbind)
- A humanized antibody fragment that binds dabigatran with an affinity 350 times greater than thrombin
- Median time to hemostasis: 2.5 hours in patients with GI, intracerebral, or traumatic bleeding
- Specific antidote for dabigatran
7b. Factor Xa Inhibitor Reversal — Andexanet Alfa (Andexxa)
- A recombinant derivative of factor Xa that acts as a decoy receptor for factor Xa inhibitors
- Has higher affinity for factor Xa inhibitors than intrinsic factor Xa
- FDA-approved for acute hemorrhage in patients on apixaban or rivaroxaban
- Current indication does not cover edoxaban or enoxaparin
- Outcomes: 92% reduction in anti-Xa activity; hemostasis judged good or excellent in most
- Important caveat: 10% of 352 patients had a thrombotic event within 30 days — FDA issued a black box warning for risk of venous and arterial thromboembolic events
7c. Emerging Reversal Agent — Ciraparantag (PER977)
- A small, synthetic, water-soluble, cationic molecule
- Binds and neutralizes: UFH, LMWH, fondaparinux, dabigatran, and factor Xa inhibitors through hydrogen bonding and charge–charge interactions
- Phase 2 trials completed in healthy volunteers — represents a universal reversal agent in development
7d. General Supportive Measures for DOAC Bleeding
- Discontinue medications interfering with hemostasis
- Compression of the bleeding site
- Volume resuscitation and transfusion support
- Antifibrinolytic therapy (e.g., tranexamic acid) for mucosal bleeding
- Activated charcoal — may remove unabsorbed dabigatran from the GI tract
- Desmopressin — for impaired platelet function in uremia or with antiplatelet agents
- PCCs or aPCCs have been used off-label but very little conclusive data exist vs. specific reversal agents
8. Laboratory Monitoring Summary
| Drug | Routine monitoring needed? | Best available test if needed |
|---|---|---|
| Dabigatran | No | Dilute TT or Ecarin Clotting Time |
| Rivaroxaban | No | Anti-Xa assay (calibrated for rivaroxaban) |
| Apixaban | No | Anti-Xa assay (calibrated for apixaban) |
| Edoxaban | No | Anti-Xa assay (calibrated for edoxaban) |
9. Key Advantages of DOACs over VKAs
| Feature | DOACs | Warfarin (VKA) |
|---|---|---|
| Pharmacokinetics | Predictable | Variable |
| Drug-drug interactions | Fewer | Many |
| Routine monitoring | Not required | Required (INR) |
| Onset | Rapid | Slow (days) |
| Half-life | Short (hours) | Long (days–weeks) |
| Intracranial hemorrhage risk | Lower | Higher |
| GI bleeding (dabigatran) | Higher | Lower |
| Reversal | Specific antidotes available | Vitamin K + PCC/FFP |
| Mechanical valve use | Contraindicated | Preferred |
Key Clinical Takeaways from Miller's Anesthesia
- DOACs do not require routine monitoring but specific tests can detect drug presence when needed
- Bridging therapy is generally not required when DOACs are held perioperatively
- ASRA 2018 guidelines guide timing of neuraxial anesthesia in patients on DOACs
- Reversal agents exist (idarucizumab for dabigatran; andexanet alfa for apixaban/rivaroxaban) but should be reserved for life-threatening hemorrhage
- Andexanet alfa carries a black box warning for thromboembolic events
- Multidisciplinary perioperative planning is essential for patients on chronic DOAC therapy
- DOACs are absolutely contraindicated in mechanical heart valve patients
Sources: Miller's Anesthesia, 2-Volume Set, 10e — Chapters 28 (Preoperative Evaluation), 46 (Hemostasis and Transfusion Medicine), 48 (Cardiac Surgery), and 65 (Ophthalmic Anesthesia)
Now shorten it to most exam answer appropriate notes including almost every important thing
NOACs / DOACs — High-Yield Exam Notes
Classification
| Class | Drug | Brand |
|---|---|---|
| Direct Thrombin Inhibitor (DTI) | Dabigatran | Pradaxa |
| Factor Xa Inhibitor | Rivaroxaban | Xarelto |
| Factor Xa Inhibitor | Apixaban | Eliquis |
| Factor Xa Inhibitor | Edoxaban | Savaysa |
Key Advantages Over Warfarin
- Predictable PK/PD → no routine monitoring needed
- Fewer drug-drug interactions
- Rapid onset, short half-life
- Lower intracranial hemorrhage risk
- Contraindicated in mechanical heart valves (use warfarin)
- LMWH preferred over DOACs in pregnancy
Indications
- Nonvalvular AF → stroke prevention
- DVT / PE → prevention & treatment
- AF + PCI → dual therapy (Xa inhibitor + P2Y12) preferred over triple therapy
Individual Drug Facts
- 150 mg BD: non-inferior to warfarin for stroke; similar overall bleeding risk
- ↑ GI bleeding, ↓ intracranial bleeding vs. warfarin
- Monitoring: aPTT unreliable; dilute TT or ecarin clotting time = tests of choice; TT very sensitive (detects presence but not quantity)
- ↓ strokes, ↓ intracranial hemorrhage, ↓ all-cause mortality vs. warfarin
- Apixaban vs. warfarin: ↓ stroke + significant ↓ major bleeding
- Monitoring: anti-Xa assay (must be individually calibrated per drug; no established therapeutic range)
Perioperative Management
| Drug | Low-risk surgery | High-risk / Neuraxial |
|---|---|---|
| Dabigatran | 24 h | 48–96 h (↑ if renal impairment) |
| Rivaroxaban | 24 h | 48 h |
| Apixaban | 24 h | 48 h |
| Edoxaban | 24 h | 48 h |
Reversal Agents
| Agent | Reverses | Mechanism | Key Points |
|---|---|---|---|
| Idarucizumab (Praxbind) | Dabigatran | Antibody fragment; binds dabigatran 350× > thrombin | Median hemostasis: 2.5 h |
| Andexanet alfa (Andexxa) | Apixaban, Rivaroxaban | Recombinant factor Xa decoy | FDA-approved; ⚠️ Black box warning: 10% thrombotic events within 30 days; NOT indicated for edoxaban or enoxaparin |
| Ciraparantag (PER977) | UFH, LMWH, fondaparinux, dabigatran, Xa inhibitors | Cationic molecule; hydrogen bonding | Phase 2 trials only; universal reversal agent |
- Stop offending agents; compression; resuscitation
- Activated charcoal (for unabsorbed dabigatran)
- Antifibrinolytics (mucosal bleeding)
- Desmopressin (platelet dysfunction/uremia)
- Reversal agents: reserve for life-threatening hemorrhage
Meta-analysis Figures (High-Yield Numbers)
- Major bleeding: RR 0.86 (95% CI 0.72–1.02) vs. warfarin
- Intracranial hemorrhage: RR 0.46 (95% CI 0.39–0.56) vs. warfarin
Quick Comparison Table
| Feature | DOACs | Warfarin |
|---|---|---|
| Monitoring | Not routine | INR required |
| Bridging needed | Usually NO | Often YES |
| Mechanical valves | ❌ Contraindicated | ✅ Preferred |
| Intracranial bleed | ↓ | ↑ |
| GI bleed (dabigatran) | ↑ | ↓ |
| Reversal | Specific antidotes | Vit K + PCC |
Using millers anaesthesiology, discuss in detail about all these topics
You are a medical library research agent. Search Miller's Anesthesia (10th edition, ISBN 9780323935920) using the query_library_db tool to find detailed content on the following topics. For EACH topic, run FTS searches, identify the relevant file paths and line numbers, then read_file to extract the full content. Return all raw extracted text organized by topic. TOPICS TO RESEARCH: 1. Cardiopulmonary bypass (CPB) — components of the CPB circuit, prime/priming solution, conduct of CPB (flows, pressures, temperature) 2. Myocardial protection — cardioplegia types (crystalloid vs blood, antegrade vs retrograde), cardioplegia composition, strategies for myocardial protection SEARCH APPROACH: - Use paragraphs_fts with MATCH terms like 'cardiopulmonary bypass circuit' AND book_title LIKE '%Miller%' - Use headings_fts with MATCH 'cardiopulmonary bypass' AND book_title LIKE '%Miller%' - Use headings_fts with MATCH 'myocardial protection' AND book_title LIKE '%Miller%' - Use headings_fts with MATCH 'cardioplegia' AND book_title LIKE '%Miller%' - Read ALL relevant sections fully (use read_file with offset/limit=100 per call, paginate as needed) Return the extracted content in full, organized by topic heading. Include page numbers where visible.
You are a medical library research agent. Search Miller's Anesthesia (10th edition, ISBN 9780323935920) using the query_library_db tool to find detailed content on the following topics. For EACH topic, run FTS searches, identify the relevant file paths and line numbers, then read_file to extract the full content. Return all raw extracted text organized by topic. TOPICS TO RESEARCH: 1. Weaning from CPB — criteria, steps, IABP (intra-aortic balloon pump) — indications, mechanism, timing, LVAD (left ventricular assist device) — types, indications 2. Anticoagulation on CPB — heparin dosing, ACT (activated clotting time) monitoring targets, protamine reversal (dose, side effects, reactions) SEARCH APPROACH: - Use headings_fts MATCH 'weaning cardiopulmonary bypass' AND book_title LIKE '%Miller%' - Use headings_fts MATCH 'intra-aortic balloon pump' AND book_title LIKE '%Miller%' - Use headings_fts MATCH 'ventricular assist device' AND book_title LIKE '%Miller%' - Use paragraphs_fts MATCH 'heparin ACT protamine' AND book_title LIKE '%Miller%' - Use headings_fts MATCH 'anticoagulation bypass heparin' AND book_title LIKE '%Miller%' - Use paragraphs_fts MATCH 'activated clotting time' AND book_title LIKE '%Miller%' - Read ALL relevant sections fully with read_file, paginate as needed Return the extracted content in full, organized by topic heading. Include page numbers where visible.
You are a medical library research agent. Search Miller's Anesthesia (10th edition, ISBN 9780323935920) using the query_library_db tool to find detailed content on the following topics. For EACH topic, run FTS searches, identify the relevant file paths and line numbers, then read_file to extract the full content. Return all raw extracted text organized by topic. TOPICS TO RESEARCH: 1. Anaesthesia for CABG — on-pump (conventional CPB) vs OPCAB (off-pump coronary artery bypass) — anesthetic management, monitoring, differences, outcomes 2. Anaesthesia for valve surgeries — specifically: - Aortic Stenosis (AS): pathophysiology, anesthetic goals, hemodynamic management - Aortic Regurgitation (AR): pathophysiology, anesthetic goals - Mitral Regurgitation (MR): pathophysiology, anesthetic goals - Mitral Stenosis (MS): pathophysiology, anesthetic goals SEARCH APPROACH: - headings_fts MATCH 'coronary artery bypass' AND book_title LIKE '%Miller%' - headings_fts MATCH 'off-pump coronary' AND book_title LIKE '%Miller%' - headings_fts MATCH 'aortic stenosis' AND book_title LIKE '%Miller%' - headings_fts MATCH 'aortic regurgitation' AND book_title LIKE '%Miller%' - headings_fts MATCH 'mitral stenosis' AND book_title LIKE '%Miller%' - headings_fts MATCH 'mitral regurgitation' AND book_title LIKE '%Miller%' - Read ALL relevant sections fully with read_file, paginate as needed Return the extracted content in full, organized by topic heading. Include page numbers where visible.
You are a medical library research agent. Search Miller's Anesthesia (10th edition, ISBN 9780323935920) using the query_library_db tool to find detailed content on the following topics. For EACH topic, run FTS searches, identify the relevant file paths and line numbers, then read_file to extract the full content. Return all raw extracted text organized by topic. TOPICS TO RESEARCH: 1. Anaesthesia for congenital heart disease — Left-to-right shunts (ASD, VSD, PDA), Right-to-left shunts (Tetralogy of Fallot), cyanotic CHD — anesthetic considerations, effects on drug uptake 2. Transoesophageal echocardiography (TOE/TEE) — standard views, indications, perioperative use in cardiac surgery, what to assess SEARCH APPROACH: - headings_fts MATCH 'congenital heart disease' AND book_title LIKE '%Miller%' - headings_fts MATCH 'left right shunt' AND book_title LIKE '%Miller%' - paragraphs_fts MATCH 'tetralogy fallot anesthesia' AND book_title LIKE '%Miller%' - headings_fts MATCH 'transesophageal echocardiography' AND book_title LIKE '%Miller%' - headings_fts MATCH 'perioperative echocardiography' AND book_title LIKE '%Miller%' - paragraphs_fts MATCH 'TEE views standard cardiac' AND book_title LIKE '%Miller%' - Read ALL relevant sections fully with read_file, paginate as needed Return the extracted content in full, organized by topic heading. Include page numbers where visible.
You are a medical library research agent. Search Miller's Anesthesia (10th edition, ISBN 9780323935920) using the query_library_db tool to find detailed content on the following topics. For EACH topic, run FTS searches, identify the relevant file paths and line numbers, then read_file to extract the full content. Return all raw extracted text organized by topic. TOPICS TO RESEARCH: 1. Low cardiac output syndrome (LCOS) — definition, diagnosis, causes, management 2. Vasoactive drugs in cardiac surgery — inotropes (dobutamine, milrinone, dopamine, epinephrine) and vasopressors (norepinephrine, vasopressin, phenylephrine) — doses, mechanisms, indications 3. Deep hypothermic circulatory arrest (DHCA) — technique, temperature targets, neuroprotection strategies, cerebral perfusion methods 4. Cardiac surgery complications — air embolism (causes, prevention, treatment), neurological injury (stroke, cognitive dysfunction) 5. TAVI/TAVR anaesthesia considerations — patient selection, access routes, anaesthetic technique (GA vs sedation), complications, hemodynamic goals SEARCH APPROACH: - headings_fts MATCH 'low cardiac output' AND book_title LIKE '%Miller%' - headings_fts MATCH 'inotropes vasopressors cardiac' AND book_title LIKE '%Miller%' - headings_fts MATCH 'deep hypothermic circulatory arrest' AND book_title LIKE '%Miller%' - paragraphs_fts MATCH 'neuroprotection circulatory arrest' AND book_title LIKE '%Miller%' - headings_fts MATCH 'air embolism cardiac' AND book_title LIKE '%Miller%' - headings_fts MATCH 'transcatheter aortic valve' AND book_title LIKE '%Miller%' - paragraphs_fts MATCH 'TAVI TAVR anesthesia' AND book_title LIKE '%Miller%' - paragraphs_fts MATCH 'neurological complications cardiac surgery' AND book_title LIKE '%Miller%' - Read ALL relevant sections fully with read_file, paginate as needed Return the extracted content in full, organized by topic heading. Include page numbers where visible.
...